DK1272633T3 - Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi - Google Patents

Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi

Info

Publication number
DK1272633T3
DK1272633T3 DK01920913.9T DK01920913T DK1272633T3 DK 1272633 T3 DK1272633 T3 DK 1272633T3 DK 01920913 T DK01920913 T DK 01920913T DK 1272633 T3 DK1272633 T3 DK 1272633T3
Authority
DK
Denmark
Prior art keywords
methods
immunostimulatory
preparations
dendritic cell
based immunotherapy
Prior art date
Application number
DK01920913.9T
Other languages
English (en)
Inventor
Reiner Laus
Damir Vidovic
Thomas Graddis
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of DK1272633T3 publication Critical patent/DK1272633T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01920913.9T 2000-03-30 2001-03-30 Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi DK1272633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19350400P 2000-03-30 2000-03-30
PCT/US2001/010515 WO2001074855A2 (en) 2000-03-30 2001-03-30 Compositions and methods for dendritic cell-based immunotherapy

Publications (1)

Publication Number Publication Date
DK1272633T3 true DK1272633T3 (da) 2011-05-23

Family

ID=22713907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01920913.9T DK1272633T3 (da) 2000-03-30 2001-03-30 Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi

Country Status (13)

Country Link
US (2) US7060279B2 (da)
EP (1) EP1272633B1 (da)
JP (1) JP5110674B2 (da)
AT (1) ATE507295T1 (da)
AU (2) AU4791901A (da)
CA (1) CA2403964C (da)
CY (1) CY1111718T1 (da)
DE (1) DE60144516D1 (da)
DK (1) DK1272633T3 (da)
ES (1) ES2362715T3 (da)
NZ (1) NZ522066A (da)
PT (1) PT1272633E (da)
WO (1) WO2001074855A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
EP1601684B1 (en) 2003-03-05 2014-10-15 Dendreon Corporation Alternative reading frame polypeptides for treatment
US7737253B2 (en) * 2006-06-16 2010-06-15 Bresagen, Inc. Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EA016818B1 (ru) * 2007-01-15 2012-07-30 Глаксосмитклайн Байолоджикалс С.А. Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
AR064863A1 (es) * 2007-01-15 2009-04-29 Glaxosmithkline Biolog Sa Proteina de fusion
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2139498B1 (en) * 2007-03-22 2015-03-18 Dendreon Corporation Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity
KR20140103122A (ko) * 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 신경교종을 치료하기 위한 조성물 및 방법
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
EP4178678A1 (en) 2020-07-07 2023-05-17 Cancure, LLC Mic antibodies and binding agents and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048981B (en) * 1979-05-23 1982-11-17 Coal Ind Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU6363094A (en) * 1993-03-15 1994-10-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide coated dendritic cells as immunogens
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5586538A (en) * 1995-11-13 1996-12-24 Caterpillar Inc. Method of correcting engine maps based on engine temperature
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
AU6897998A (en) * 1997-04-11 1998-11-11 Dendreon Corporation Composition and method for inducing an immune response against tumour-rela ted antigens
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
NZ512807A (en) * 1998-12-14 2003-10-31 Dendreon Corp Compositions and methods for enhancement of major histocompatibility complex class 1 restricted antigen presentation by attaching the antigen to a specific peptide
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
AU764969B2 (en) * 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease

Also Published As

Publication number Publication date
WO2001074855A3 (en) 2002-03-07
US7659117B2 (en) 2010-02-09
US20020061310A1 (en) 2002-05-23
US7060279B2 (en) 2006-06-13
CA2403964A1 (en) 2001-10-11
EP1272633A2 (en) 2003-01-08
US20050232932A1 (en) 2005-10-20
NZ522066A (en) 2004-08-27
ES2362715T3 (es) 2011-07-12
ATE507295T1 (de) 2011-05-15
DE60144516D1 (de) 2011-06-09
PT1272633E (pt) 2011-06-27
JP2003529608A (ja) 2003-10-07
AU2001247919B2 (en) 2006-02-09
JP5110674B2 (ja) 2012-12-26
WO2001074855A2 (en) 2001-10-11
CY1111718T1 (el) 2015-10-07
CA2403964C (en) 2013-04-30
AU4791901A (en) 2001-10-15
EP1272633B1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
CY1111718T1 (el) Συνθεσεις και μεθοδοι για ανοσοθεραπεια βασιζομενη σε δενδριτικα κυτταρα
DK0870022T3 (da) Immunstimulerende sammensætning og fremgangsmåde
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
HK1058367A1 (en) Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of thes proteins
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
WO2001029233A3 (en) Chimeric immunogenic compositions and nucleic acids encoding them
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
BR9406652A (pt) Composição
ATE437228T1 (de) Dendritzell-spezifische kostimulierende moleküle
WO2003045128A3 (en) SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
ATE389397T1 (de) Adjuvante zusammensetzungen
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
AU2363301A (en) Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide